As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years these have been printed in the December Issue, but for your convenience and for environmental consciousness, the indexes will now be available electronically.
dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel for acne in adolescents, 1395
Epiduo® pediatric acne study (CTR), 1155
Galdersma receives approval for Differin® (adapalene) lotion 0.1% (PP), 723
generic approval of adapalene cream 0.1% (PP), 639
irritation potential of tretinoin gel microsphere pump vs. adapalene plus benzoyl peroxide gel, 998
properties of benzoyl peroxide, combined with, 482
randomized clinical studies of adapalene lotion for acne, 639
safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549
trends in use for acne vulgaris, 519
AER071, dose finding study assessing psoriasis area and severity index in patients with plaque psoriasis (CTR), 285
Afamelanotide, Clinuvel Pharmaceuticals gets FDA approval for light intolerance drug trial (CR), 627
Aging skin. See Cutaneous aging
AIN457, regimen finding study in psoriasis (CTR), 285
Albacozone, study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
Alcoholics, treatment of psoriasis in (CR), 405
Alefaccept how and when to use biologics in psoriasis and, s106 (August)
treatment of psoriasis for up to one year, 1491
use of biologic agents in pediatric psoriasis and, 975
Alemuzumab, followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883
Allium cepa, medical and surgical management of keloids and, 1249
Aloe vera, botanical approaches to alopecia and, 537
Alopecia botanical approaches to, 537
hair growth in patients with alopecia areata totalis after treatment with simvastatin and ezetimibe (CR), 62
Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
minoxidil for female pattern hair loss (CTR), 1446
new study implicates autoimmune mechanisms in alopecia areata (PP), 1160
pathogenesis, genetics and medical treatment of patterned hair loss, 1412
safety and pharmacokinetics of new formulation of bimatoprost in (CTR), 1446
spironolactone pills vs. minoxidil lotion in female pattern hair loss (CTR), 577
treatment of alopecia areata of scalp with intra-dermal injections of botulinum toxin (CR), 82
treatment of androgenetic alopecia in females (PP), 1446
Anorexia nervosa, dermatologic indicators of (NVR), 412
Antiepileptic drugs, postpubertal eruptive syringoma triggered with (CR), 707
Antifungal drugs antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
comparison of SUBA™-itraconazole with SPO-RANOX™ for onychomycosis (CTR), 187, 285, 425
cutaneous fixed drug eruption to fluconazole (CR), 1025
efficacy and safety of long-term treatment with terbinafine gel in onychomycosis (CTR), 577, 1155
efficacy of itraconazole in BCC (CTR), 883, 1035
flucloxacillin-associated Stevens-Johnson syndrome (CR), 1272
onychomycosis therapy, 1109
pharmacokinetics and safety of fluconazole solu- tion in distal subungual onychomycosis (CTR), 577, 1155
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538
study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
TDT 067 onychomycosis study (CTR), 1538
Antihistamines safety and efficacy of abatacept for chronic urticaria after inadequate response to (CTR), 86, 1155
second-generation, for chronic idiopathic urti- caria, 503
topical, efficacy for pruritus, 992
Antihypertensive drugs, oral lichenoid drug reac- tion associated with hypoglycemic drugs and (CR), 73
Antimicrobial drugs acne relapse rate of oral minocycline vs. oral doxycycline combined with topical tretinoin, 405
followed by topical tretinoin alone (CTR), 572, 727
antibacterial effects of a chitosan-containing spray, 1237
antimicrobial efficacy of benzoyl peroxide/ clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for acne vulgaris, 131
avoiding antimicrobial resistance in treatment of acne vulgaris, 519
benzoyl peroxide–clindamycin combinations and skin hydration changes in rosacea comorbidities and treatment utilization over time, 1402
development of antimicrobial resistance due to antibiotic treatment of acne, 855
efficacy and safety of doxycycline and minocyc- line for acne, 1407
efficacy of metronidazole in treatment of cutan- eous and mucosal lichen planus, 1186
efficacy of topical azelaic acid gel plus oral doxycycline gel plus oral doxycycline in rosacea, 607
FDA Advisory Committee recommends approval of ceftaroline fosamil (PP), 1552
management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241
Tamiflu®: what dermatologists need to know (NVR), 76
oregano-based ointment with antimicrobial activ- ity against MRSA, 377
retapamulin in age of S. aureus resistance to, 1198
retapamulin vs. linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538
safety and efficacy of CEM-102 vs. linezolid in bacterial skin infections (CTR), 1538
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 426, 1035, 1538
safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82
sales of Zetfera stopped in Canada (PP), 874
tigecycline linked to increased mortality risk (PP), 1495
TR-701 for bacterial skin infections (CTR), 1538
using off-patent antibiotics for MRSA (CR), 1538
Antioxidants controlled multi-center study evaluating the effi- cacy of Vivéti Skin Care for photaging of face, eye and mouth, 22
dose-dependent antioxidant function of resvera- trol, 1523
efficacy and tolerance of novel phenolic antioxi- dant skin care system, 1480
N-acetylcysteine to reduce melanoma risk (PP), 183
oxidative damage, skin aging, antioxidants and a
novel antioxidant rating system, 11
Anti–tumor necrosis factor (TNF) therapy atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab, 57
cutaneous lupus erythematosus and (CR), 1283
drug-associated acne and acneiform eruptions, 627
efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82
etanercept for chronic urticaria (CTR), 1155
etanercept for familial pityriasis rubra pilaris (CR), 844
etanercept for recalcitrant cicatricial pemphigoid (CR), 68
etanercept in lichen planus (CTR), 187, 425, 577
how and when to use biologics in psoriasis and, s106 (August)
injectable biologic and U0279 combination therapy for psoriasis (CTR), 285
long-term safety and efficacy of etanercept in psoriasis, 928
prospective new biologic therapies for psoriasis and psoriatic arthritis, 947
rapid improvement of pyoderma gangrenosum after infliximab treatment (CR), 702
safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577
safety and effectiveness of etanercept for lichen planus or oral mucosa or skin (CTR), 883
safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538
safety and effectiveness of ustekinumab in psoriatic arthritis patients who have prior exposure to anti–TNF agents (CTR), 1155
use in pediatric psoriasis, 975
ustekinumab vs. etanercept for psoriasis (PP), 572

Antiviral drugs EPB-348 for herpes zoster (CTR), 1035
FV-100 vs. valacyclovir for herpes zoster (CTR), 1035
Mylan receives approval for generic Valtrex® (PP), 1033
safety and pharmacokinetics of famiclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285

Anxiety, relaxation strategies for patients during dermatologic surgery, 795

Apremilast in atopic or contact dermatitis (CTR), 187
for lichen planus (CTR), 572, 883
for moderate-to-severe acne (CTR), 727, 1155, 1289, 1446
positive phase 2b clinical trial for psoriasis treatment (PP), 282
for rosacea (CTR), 722, 1035, 1538
safety study of clinical and immune effects in cutaneous lupus (CTR), 1538

Arginine butyrate, plus standard local therapy in patients with refractory sickle cell ulcers (CTR), 1289

Argyria, localized, secondary to acupuncture (CR), 1019

Aripiprazole, drug-associated acne and acneiform eruptions, 627

Artefill®, for correction of atrophic acne scars, 1062

Arthritis pancreatitis, panniculitis and polyarthritis syndrome (CR), 1145
psoriatic adult onset, crotalizumab pegol for (CTR), 1446
typical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on

Infliximab therapy (CR), 57
prospective new biologic therapies for psoriasis and, 947
safety and efficacy of ustekinumab in patients who have prior exposure to anti–TNF agents (CTR), 1155

Ascheron's syndrome, drug therapy for, 341
Asclera. See Polidocanol
APSO15K, efficacy and safety in psoriasis (CTR), 1035, 1446
Atacicept, in generalized systemic lupus erythematosus (CTR), 1538

Atopic dermatitis adherence and efficacy of desonide hydrogel for, 324
anakinra for (CTR), 1035, 1155, 1446
apremilast in contact dermatitis or (CTR), 187
cost-effectiveness of tacrolimus ointment vs. pimecrolimus cream for, 372
effect of pimecrolimus cream on calcified lesions in eczema (CTR), 883
efficacy of triamcinolone 0.1% cream occluded with hydrogel patch vs. triamcinolone 0.1% cream without occlusion for (CTR), 883
evidence-based review of coal tar preparations for, 1258
management of pruritus with Xyzal in (CTR), 82
mylecophenolat mofetil for chronic dermatitis, 356
nonsteroidal lamellar matrix cream containing palmitoylethanolamide for, 334
pediatric indication for Locoid Lipocream® cream (PP), 883
pediatric longitudinal evaluation of long-term safety of Protopic® for (CTR), 1446
in pregnancy (NVR), 1297
pruritus in, 488
safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1035, 1155, 1446
topical vitamin B12 for children with (CTR), 1155, 1446
treatment with concurrent Altabax® and topical vs. hydroquinone in melasma (CTR), 727

Azelaic acid efficacy in psoriasis, 964
efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607
vs. hydroquinone in melanoma (CTR), 727

B

Basal cell carcinoma (BCC) BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1035
celcexib inhibition of genetic BCC (PP), 418
efficacy and safety of GSK-449 in patients with advanced BCC (CTR), 85, 289
efficacy of iraconazole in (CTR), 883, 1035
efficacy of PDT for recurrent SCC and BCC, 122
electronic brachytherapy for non-melanoma skin cancer (CTR), 1035
flexible scalpels for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
fractional photothermolysis for depressed alar scar following Mohs micrographic surgery for (CR), 66
multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035

of nasal pyramid, intrallesional interferon alfa-2b for, 381
patient with nevoid BCC syndrome treated successfully with PDT (CTR), 167
rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 678
safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035

Behçet's disease multiple skin cancers in a patient on combination immunosuppressive therapy for (CR), 152
thalidomide and analogues for, 814

Benzoyl peroxide (BPO) antimicrobial efficacy of benzoyl peroxide/calcipotriol combination for psoriasis, 1289
Calcipotriol vs. hydroquinone in melasma (CTR), 727

Betamethasone dipropionate, safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969

Bevacizumab for angiosarcoma (CTR), 285
gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285

Bexarotene development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CTR), 1014
systemic retinoids for chemoprevention of nonmelanoma skin cancer in high-risk patients, 753

BFH722, safety and efficacy in psoriasis patients (CTR), 187, 425

Bicillin LA, vs. placebo for psoriasis unresponsive to topical medications (CTR), 425

Bimatoprost for correction of atrophic acne scars, 1062

Benzyl alcohol lotion 5%, for head lice (PP), 572

Beta-blockers for chronic wound healing (CTR), 727
drug-associated acne and acneiform eruptions, 627

Betamethasone dipropionate, safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969

Bevacizumab for angiosarcoma (CTR), 285
gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285

Bexarotene development of Hodgkin’s lymphoma under bexarotene treatment for Sézary syndrome (CTR), 1014
systemic retinoids for chemoprevention of nonmelanoma skin cancer in high-risk patients, 753

BFH722, safety and efficacy in psoriasis patients (CTR), 187, 425

Bicillin LA, vs. placebo for psoriasis unresponsive to topical medications (CTR), 425

Bimatoprost ophthalmic solution, in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446
Biosictrizole, sunscreen update: controversies, what's safe, what's next (NVR), 1451
Blepharospasm, acetyl hexapeptide-8 (AH8) in treatment of (CTR), 82
Blue light therapy, current guide to laser and light-based therapies for acne, 614
BMS-833923 (XL139), in advanced or metastatic cancer (CTR), 883, 1035
Body contouring PureGraft™ System receives marketing clearance (PP), 723
Zeltiq receives FDA clearance (PP), 1552
Body image disturbance, in patients with acne (RR), 725
Bone, osteoinductive subungal melanoma (CR), 159
Botanical products for actinic keratosis, s45 (May) for alopecia, 537
cosmeceuticals in clinical practice, s62 (May)
Botulin toxin cost effectiveness for treatment of depression, 27 current and future botulinum neurotoxin type A preparations in aesthetics, 1065 expanding the use of neurotoxins in facial aesthetics, s7 (January)
failure of treatment for localized vitiligo, 1092
FDA approves Merz Pharmaceuticals' Xeomin® (PP), 1455
formulation composition of botulinum toxins in clinical use, 1085 histopathologic identification of dermal filler agents, 1072 hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135 injection techniques for revolumization of perioral region with hyaluronic acid, 367 localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399 Mederma® for stretch marks (PP), 418
minimally invasive techniques for periorbital rejuvenation, s118 (August)
monophasic, cohesive-polysulfated-matrix crosslinking-technology-based HA filler for facial lipoatrophy in HIV-infected patients (CR), 690
pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
retrospective review of 500 patients treated with abobotulinumtoxinA, 1081
treatment of alopecia areata of scalp with intra-dermal injections of (CTR), 82
treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538
Brachytherapy, electronic, for non-melanoma skin cancer (CTR), 1035
Breast surgery, safety and efficacy of EXC 001 to improve appearance of scars from (CTR), 728
Briakinumab See also Biologics for psoriasis and psoriatic arthritis, 947 use in pediatric psoriasis, 975 Brown recluse spider bite, drug therapy for, 341 Bulimia nervosa, dermatologic indicators of (NVR), 412 Bullous skin disorders autoimmune, hematopoietic stem cell support in patients with (CTR), 1289 efficacy and safety of omalizumab in bullous pemphigoid (CTR), 187, 425, 577, 1289 Bupropion, Stevens-Johnson syndrome with acute psoriatic exacerbation induced by (CR), 1010 Burn scars ablative fractional treatment of mature scars (CR), 389 appearance after CO2 fractional laser treatment (CTR), 727 CO2 fractional laser treatment of (CR), 173 efficacy of spray silicone in alteration of (CTR), 727 Buruli ulcer, drug therapy for, 341 Calciniphylaxis drug therapy for, 341 warfarin-induced skin necrosis mimicking (CR), 859 Calcipotriene FDA approves Glenmark's calcipotriene ointment (PP), 723 safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969 Calcium dobesilate, combination therapy for rosacea (CTR), 187, 285, 425, 1538 Calcium hydroxyapatite fillers for facial shaping, s129 (August) histopathologic identification of dermal filler agents, 1072 in nonsurgical aesthetic rejuvenation, 446 pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577 Capecitabine, increased mast cell density in hand-foot syndrome induced by (CR), 268 Capsaicin for alopecia, 537 FDA approves Qutenza® for postherpetic neuralgia (PP), 282 Cardiac catheterization dye, fatal toxic epidermal necrolysis due to (CR), 837 Carotenoid levels in skin, correlation with previous history of skin cancer (CTR), 1289 Cathelicidin, effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883 CC-10004, See Aprimelast CDDT223 gel, efficacy and safety study in subjects with acne (CTR), 1446 CDDT0805/47 gel, efficacy and safety in subjects with facial erythema associated with rosacea (CTR), 1538 CDP 870, See Certolizumab pegol Cefaroline fosamil, FDA Advisory Committee recommends approval of (PP), 1562 Cefotibiprole, sales stopped in Canada (PP), 874 Celecoxib, inhibition of genetic BCC by (PP), 418 CEM-102, safety and efficacy vs. linezolid in bacterial skin infections (CTR), 1538 Cephalaxin, using off-patient antibiotics for MRSA (CTR), 1538 Certolizumab pegol (CDP 870) for adult onset psoriatic arthritis (CTR), 1446 for psoriasis and psoriatic arthritis, 947 Cetirizine, for chronic idiopathic urticaria, 503 Cetuximab, cutaneous reactions to epidermal growth factor receptor inhibitors, 1229 Charcot-Marie-Tooth disease, multiple malignant melanomas and (CR), 164 Chemotherapy bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577 botanicals for alopecia due to, 537 erosion secondary to Taxotere (CR), 1534 gemtuzumab and dactoxel with or without bevacizumab in leiomysarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285 increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268 for infantile hemangiomas (NVR), 176 management of Merkel cell carcinoma with emphasis on small primary tumors, 105 sorafenib-induced psoriasisfom eruption in patient with metastatic thyroid carcinoma
urticarial hypersensitivity reaction caused by treatment of cutaneous T-cell lymphoma with topi-
arginine butyrate plus standard local therapy in apremilast for rosacea (CTR), 727, 1035, 1538
apremilast for moderate-to-severe acne (CTR), 883, 1035, 1155, 1289
apremilast for lichen planus (CTR), 577, 883
antibacterial effects of a chitosan-containing
anakinra for atopic dermatitis (CTR), 1035, 1155, 1177
alemtuzumab followed by peripheral stem cell
AIN457 regimen finding study in psoriasis (CTR), 727, 1035, 1155, 1289
safety and efficacy of clindamycin and tretinoin
gel for rosacea (CTR), 187, 285, 425, 1035, 1538
properties of benzoyl peroxide combined with,
482
safety and efficacy of clindamycin and tretinoin
gel for rosacea (CTR), 187, 285, 425, 1035, 1155
use of off-patent antibiotics for MRSA (CTR), 1538
Clinical trial review (CTR), 82, 187, 285, 425, 1035, 1155, 1289, 1446, 1538
Clinical trials
acetyl hexapeptide-8 (AH8) in treatment of
blepharospasm (CTR), 82
acne relapse rate of oral minocycline vs. oral
minocycline combined with topical tretinoin,
followed by topical tretinoin alone (CTR), 577, 727
AIN457 regimen finding study in psoriasis (CTR), 285
ALA-PDT vs. vehicle PDT for AK and reduction of
new non-melanoma skin cancer in solid organ
transplant recipients (CTR), 82
alemzumab followed by peripheral stem cell
transplantation in advanced mycosis fungo-
des/Sézary syndrome (CTR), 883
anaknir for atopic dermatitis (CTR), 1035, 1155,
1446
antibacterial effects of a chitosan-containing
spray, 1237
anti-inflammatory effects of topical dapsone for
acne, 667
apremilast for lichen planus (CTR), 727, 883
apremilast for moderate-to-severe acne (CTR), 727, 1155, 1289, 1446
apremilast for rosacea (CTR), 727, 1035, 1538
apremilast in atopic or contact dermatitis (CTR), 187
arginine butyrate plus standard local therapy in
patients with refractory sickle cell ulcers (CTR), 1289
assessment of mechanisms of improved wound
healing (CTR), 727
atacicept in generalized systemic lupus erythema-
tosus (CTR), 1538
Atralin gel for rosacea (CTR), 1035, 1538
azelaic acid vs. hydroquinone in melasma (CTR),
727
benzoyl peroxide-clindamycin combinations and
skin hydration (PP), 80
comparative study of tolerability of two combina-
tion therapies for acne (CTR), 187, 425
dristizumab pegol for adult onset psoriatic arthri-
tis (CTR), 1446
clinical activity, safety, and tolerability of SRT2104
in subjects with psoriasis (CTR), 1446
Clinuvel Pharmaceuticals gets FDA approval for
light intolerance drug trial (PP), 723
combination stem cell therapy for treatment of
severe lichen sclerosis (CTR), 1289
combination therapy for rosacea (CTR), 187, 285,
425, 1538
comparative study of tolerability of two combina-
tion therapies for acne (CTR), 187, 425
comparison of RevLite Electro-optic Q-switched
neodymium-doped yttrium aluminium garnet
laser to a fractionated laser system (CTR), 82,
187, 425, 1035, 1155, 1289
comparison of safety and efficacy of ALA plus a
532 nm KTP laser vs. 532 nm KTP laser alone
for facial acne, 229
comparison of SUBA™-itraconazole with SPO-
RANOX® for onychomycosis (CTR), 187, 285,
425
complete lymph node dissection or observation in
treating patients with localized melanoma and
sentinel node metastasis (CTR), 727
controlled multi-center study evaluating the effi-
cacy of Vivite Skin Care for photoaging of face,
eye and mouth, 22
correlation between skin cartenoid levels and
previous history of skin cancer (CTR), 1289
dapsone gel 5% for dermatitis herpetiformis
(CTR), 1155
dapsone gel in combination with adapalene gel,
benzoyl peroxide gel or moisturizer for acne
vulgaris, 33
dasatinib for unselectable or metastatic SCC
(CTR), 285
dasatinib for unselectable or metastatic SCC or
RAI stage 0–1 chronic lymphocytic leukemia
(CTR), 1538
dose finding and safety study of oral LEQ056 in
patients with advanced solid tumors (CTR), 883
dose finding study of AE8071 assessing psoriasis
area and severity index in patients with plaque
psoriasis (CTR), 285
effect of lidocaine when mixed with large gel
particle hyaluronic acid filler on tolerability
and longevity, 1097
effect of pimecrolimus cream on catheridcin
levels in eczema (CTR), 883
effect of thymosin beta-4 on wound healing in
cutaneous melanosoma (CTR), 727
effects of fractional carbon dioxide laser treat-
ment prior to wound closure (CTR), 1155
effects of pulsed-dye laser on scar formation
(CTR), 727, 1155
effects of Kalatan, Travatan and Lumigan of skin
pigmentation near eye (CTR), 1289
efficacy and safety of adding methotrexate to
tanecure in psoriasis (CTR), 82
efficacy and safety of ASP015K in psoriasis (CTR),
1035, 1446
efficacy and safety of CD077223 gel in subjects
with acne (CTR), 1446
efficacy and safety of CD07805/47 gel in subjects
with facial erythema associated with rosacea
(CTR), 1538
efficacy and safety of GDC-0449 in patients with
advanced BCC (CTR), 82, 285
efficacy and safety of iontophoretic application of
terbinafen gel in onychomycosis (CTR), 577,
1155
efficacy and safety of omalizumab in bullous
pemphigoid (CTR), 187, 425, 577, 1289
efficacy and safety of Visonac PDT for acne (CTR),
1155, 1289, 1446
efficacy and safety study of 3.75% imiquimod
cream following cryosurgery for AK, 1101
efficacy and tolerance of novel phenolic antioxi-
dant skin care system, 1480
efficacy of 15% azelaic acid in psoriasis, 964
efficacy of hexapeptide-7 in menopausal skin, 49
efficacy of irtraconazole in BCC (CTR), 883, 1035
efficacy of spray silicone in alteration of burn scar
(CTR), 727
efficacy of triaminolone 0.1% cream occluded
with hydrogel patch vs. triaminolone 0.1% cream
without occlusion for eczema (CTR), 883
efficacy of Ultravate ointment in combination with
Lac-Hydrin cream for psoriasis (CTR), 285, 577,
1035
electron beam brachytherapy for non-melanoma skin
cancer (CTR), 1035
Emervel Classic Lidocaine vs. Juvederm Ultra
Plus for facial wrinkles and folds (CTR), 1538
Emervel Deep Lidocaine vs. Juvederm Ultra Plus
for facial wrinkles and folds (CTR), 1538
EPB-348 for herpes zoster (CTR), 1035
Epipen® pediatric acne study (CTR), 1155
erlotinib and radiotherapy for cutaneous SCC
(CTR), 82, 285
erlotinib for psoriasis (CTR), 82, 187, 285, 425,
577, 1035, 1446
erlotinib in women with SCC of vulva (CTR), 1289
erlotinib prior to surgery or radiation in patients
with SCC (CTR), 883, 1289
Ertaczo® relieves itching (PP), 80
etanercept for chronic urticaria (CTR), 1155
etanercept in lichen planus (CTR), 187, 425, 577
evaluation of single dose of UV-B95 in psoriasis
subjects (CTR), 285, 577, 1035, 1446
exSALT SD7™ compared to Xeroform® petrola-
tum dressing for management of partial thick-
ness donor sites (CTR), 727
face and neck revitalization with platelet-rich
plasma, 466
fluphenazine hydrochloride for psoriasis (CTR),
187, 425, 1446
FV-100 vs. valacyclovir for herpes zoster (CTR),
1446
ganciclovir and docetaxel with or without bevaca-
zumab in leiomysarcoma, malignant fibrous
histiocytoma and angiosarcoma (CTR), 290
GSK2132231A antigen-specific immunothera-
petic in patients with inoperable metastatic
cutaneous melanoma (CTR), 727, 1289
Hairmax Lasercomb for androgenetic alopecia
in females (CTR), 1446
hydrocortisone, silicon and vitamin E lotion for keloids and hypertrophic scars, 514
for infantile hemangiomas (NVR), 176
inflammatory hemangiomas, immune function
impairment by (PP), 1033
pediatric indication for Locoid Lipocream® cream
(PP), 80
safety and HPA axis effects of two-compound ointment containing calcipotriene/betametha-
sone dipropionate for psoriasis, 969
therapy with shampoos for targeting symptoms of inflammatory scalp disorders, 41
treatment of atopic dermatitis with concurrent Al-
tabax® and topical low-potency corticosteroids
vs. low-potency corticosteroid monotherapy
(CTR), 883, 1035
versus. tacrolimus for pruritus in atopic dermati-
is, 488
in treatment of morphea, 1213
Cosmetic dermatology
attaining predictable aesthetic results with dermal fillers, 468
Belotero dermal filler close to FDA approval (PP), 1455
calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 448
collagen-laden multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22
correction of atrophic acne scars with Artefill®, 1062
cosmeceuticals in clinical practice, s62 (May)
current and future botulinum neurotoxin type A preparations in aesthetics, 1066
dermal defects of nanoparticles, 475
effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1057
efficacy and tolerance of novel phenolic antioxidant
dermat skin care system, 1480
Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
expanding the use of neurotoxins in facial aesth-
etics, s7 (January)
face and neck revitalization with platelet-rich plasma, 466
failure of botulinum toxin treatment for localized vitiligo, 1092
FDA approves Juvederm® XC with lidocaine (PP), 418
first fractional laser FDA cleared for stretch marks (PP), 418
formula composition of botulinum toxins in clinical use, 1085
histopathologic identification of dermal filler agents, 1072
hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy (BC), 1135
injection techniques for revolumization of perioral region with hyaluronic acid, 367
lip tenting technique, 559
localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399
Mederma® for stretch marks (PP), 418
minimally invasive techniques for periorbital rejuvenation, s118 (August)
non-thermal skin tightening system for periorbital rhyt-
idies, 1121
pain with dinitrofluorosilicic acid with lidocaine for nasolabial folds (CTR), 577
practical applications of a new botulinum toxin, s31 (March)
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
PureGraft™ System receives marketing clearance (PP), 723
retrospective review of 500 patients treated with abobotulinumtoxinA, 1081
SkinMedica launches new Rejuvenize Peel™ (PP), 418
SmartLipo Triplex™ for liposuction (PP), 80
Solta Medical to buy Aesthera Corp. (PP), 418
treatment of facial atrophic scars with Esthélis, 1507
use of injectable poly-L-lactic acid in people of color, 451
Zerona now FDA-approved for body slimming (PP), 1455
Cost effectiveness, of botulinum toxins for treat-
mament of depression, 27
Cromanguard, drug therapy for, 341
Cryoderm, drug-associated acne and acneiform eruptions, 627
Cryopneumatic technology, stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by, 1528
Cryosurgery for actinic keratoses, s45 (May)
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101
medical and surgical management of keloids, 1249
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treat-
ments (CR), 864
CTLA4 therapy, autoimmune complications of (CR), 1432
Cutaneous aging. See also Photoaging
cutaneous aging study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22
efficacy of hexapeptide-7 on menopausal skin, 49
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101
Cutaneous angioimmunoblastic T-cell lymphoma (CR), 851
Cutaneous lupus erythematosus anti-TNF-á therapy and (CR), 883
Cytokines, effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330
Dabo, for alopecia, 537
Dactinomycin, drug-associated acne and acneiform eruptions, 627
Danazol, drug-associated acne and acneiform eruptions, 627
Dantrolene, drug-associated acne and acneiform eruptions, 627
Dapsone anti-inflammatory effects of topical dapsone for acne, 667
dapsone gel 5% for dermatitis herpetiformis (CTR), 1155
dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
drug-associated acne and acneiform eruptions, 627
free glucose-6-phosphate dehydrogenase–deficient and sulfonamide-allergic patients, 532
Dasatinib for unresectable or metastatic SCC (CTR), 285
for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
Decubitus ulcers, oxandrolone treatment of (CR), 711
Delusions of parasitosis, aripiprazole for (CR), 1531
Dendritic cells in immunotherapy potential role for complement in immune evasion by Mycobacterium leprae, 1373
treatment of dendritic cell control of T-cell subsets (editorial), 1364
T cells and, 1382
TH17 in regression of metastatic melanoma to topical dicyprymone, 1368
Depression, cost effectiveness of botulinum tox-
inus for treatment of, 27
Demarcoder, for detecting malignant skin lesions (CTR), 883
Dermatitis herpetiformis, dapsone gel 5% for (CTR), 1155
Dermatologists approaching psoriasis: patient-physician relations-
ships, patient education and choosing the right topical vehicle, 908
identifying the right dermatologic surgery fellow-
ship for you (RR), 421
Dermatomyositis, Wong type, 1475
Dermoscopy, impact on skin cancer diagnostics, 129
Desloratadine, for chronic idiopathic urticaria, 503
Desonide, hydroxylation, adherence and efficacy for atopic dermatitis, 324
Devices and Equipment
AccuView DVS Multi Imaging System (PP), 418
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82,
187, 425, 1035, 1155, 1289

FDA 510(k) clearance of Fraxel restore Dual Laser for AK (PP), 1552
FDA approval of eMatrix device (PP), 572
FDA approves Exilis body shaping as nonsurgical device (PP), 874
FDA approves Ulthera’s ultrasound product (PP), 282
FDA panel makes tanning bed recommendations (PP), 874

flexible scalpel for minimally invasive and minimally scarring surgery for large scalp lesions, 1268
Groove Optic™ for Lux2940™ for fractional skin resurfacing (PP), 183
Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
modified scalpel in hair restoration, 1266
MyoScience Tissue Remodeling Device for facial rejuvenation (CTR), 577

novel sonic infusion system for periornital rhytides, 1121
PureGraft™ System receives marketing clearance (PP), 723
single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341
tattoo treatment with alexandrite laser with two Nd:YAG laser handpieces pumped by alexandrite treatment beam, 1333
TempASSURE device (PP), 418
trial of DermaDermc for detecting malignant skin lesions (CTR), 883
VCTRA M3 facial imaging system (PP), 418
Zeltiq receives FDA clearance (PP), 1552
Zerona now FDA-approved for body slimming (PP), 1455

Diabetes mellitus
iron overload and diabetic wounds (NVR), 719
prompt biological therapy speeds diabetic foot ulcer healing (PP), 1455
safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82

Diet/nutrition, Heliocare® (PP), 183

prompt biological therapy speeds diabetic foot ulcer healing and diabetic wounds (NVR), 719

safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82

Diet/nutrition
Heliocare® (PP), 183

Diuretics

drug resistance, 1198

Drug reactions/toxicity
annular leukocytoclastic vasculitis associated with sorafenib (CR), 697
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbaration (CR), 1010
cutaneous cutaneous fixed drug eruption to fluconazole (CR), 1025
cutaneous lupus erythematosus and anti-TNF-α therapy (CR), 1283
cutaneous nontuberculous mycobacterial abscesses associated with insulin injections (CR), 1439
cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
dermatologic emergencies (NVR), 1546
development of Hodgkin’s lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022
drug-associated acne and acneiform eruptions, 627

Drug delivery
hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500
stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by cryopneumatic and photopneumatic technologies, 1528

Drug reactions/toxicity
annular leukocytoclastic vasculitis associated with sorafenib (CR), 697
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57

E
Eating disorders, dermatologic indicators of (NVR), 412
Ecallantide, FDA approval for hereditary angioedema (PP), 572

Economic issues

cost effectiveness of botulinum toxins for treatment of depression, 27
cost-effectiveness of tacrolimus ointment vs. pimecrolimus cream for atopic dermatitis, 372
Solta Medical to buy Aesthera Corp. (PP), 418

Efalizumab
how and when to use biologics in psoriasis, s106 (August)
progressive multifocal leukoencephalopathy in two psoriasis patients treated with (CR), 1005
resistant plaque psoriasis (PP), 183
use in pediatric psoriasis, 975

Emergencies, dermatologic (NVR), 1545
EPB-348, for herpes zoster (CTR), 1035

Epidermal growth factor receptor inhibitors
cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
drug-associated acne and acneiform eruptions, 627
drug resistance, 1198

Epidermolysis bullosa

tigecycline linked to increased mortality risk (PP), 1455

Epidermolysis bullosa
tigecycline linked to increased mortality risk (PP), 1455

Erlotinib
cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
drug-associated acne and acneiform eruptions, 627
prior to surgery or radiation in patients with SCC (CTR), 883, 1289
for psoriasis (CTR), 82, 187, 285, 425, 577, 1035, 1466
and radiotherapy for cutaneous SCC (CTR), 82, 285

Ertaczo®. See Sertaconazole nitrate cream

Eruptive syringoma
postpubertal, triggered with antiepileptic drugs (CR), 707

Estrogen

drug resistance, 1198
avoiding antimicrobial resistance in treatment of acne, 519
development of antimicrobial resistance due to antibiotic treatment of acne, 655
methylcillin-resistant S. aureus infection, new antibiotics for, and (NVR), 278
oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73
progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005
red man syndrome (NVR) and, 76
sorafenib-induced psoriasisiform eruption in patient with metastatic thyroid carcinoma (CR), 169
Tamifu®, and 76
tigecycline linked to increased mortality risk (PP), 1455
utricular hypersensitivity reaction caused by temozolomide (CR), 1142
voriconazole-induced photosensitivity/photaging in X-linked chronic granulomatous disease (CR), 562
warfarin-induced skin necrosis mimicking calciphylaxis (CR), 859

Ethyridia

drug resistance, 1198

Erythema nodosum leprosum
thalidomide and analogues for, 814

Erythromelalgia

gabapentin for (CR), 565

Estrogen

efficacy of hexapeptide-7 on menopausal skin, 49

Ethanercept
for chronic urticaria (CTR), 1155
for familial pityriasis rubra pilaris (CR), 844
how and when to use biologics in psoriasis, s106 (August)
in lichen planus (CTR), 187, 425, 577
long-term safety and efficacy in psoriasis, 928
for recalcitrant cicatricial pemphigoid (CR), 68
safety and efficacy for lichen planus of oral mucosa or skin (CTR), 577, 883

Ezetimibe

efficacy and safety of adding methotrexate to, in treatment of rheumatoid arthritis (CR), 1014

effectiveness of tacrolimus ointment vs. pimecrolimus cream for atopic dermatitis, 372
Solta Medical to buy Aesthera Corp. (PP), 418

Efalizumab, drug therapy for, 341

Eczema. See Atopic dermatitis

Editorials
Miami heat (editorial), 208
role of complement in dendritic cell control of T-cell subsets, 1364
we are making progress with acne and rosacea, 603

Erlotinib

cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
drug-associated acne and acneiform eruptions, 627
drug-associated acne and acneiform eruptions, 627

drug resistance, 1198
versus ustekinumab for psoriasis (PP), 572
Etretinate, drug-associated acne and acneiform eruptions, 627
EXC 001, safety and efficacy to improve appearance of scars from prior breast surgery (CTR), 728
Exfoliative erythroderma (NVR), 1545
exSALT SD7™, compared to Xeroform® petrolatum dressing for management of partial thickness donor sites (CTR), 727
Eye drops, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
Eyebrow
bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
Eyelashes, bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
Eyelid, acetyl hexapeptide-8 (AH8) in treatment of blepharospasm (CTR), 82
Ezetimibe, hair growth in patients with alopecia areata totalis after treatment with simvastatin and (CR), 62

Facial lipoatrophy, monophasic, cohesively-polydensified-matrix crosslinking-technology-based HA filler for facial lipoatrophy in HIV-infected patients (CR), 690
Facial rejuvenation
Calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446
Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
face and neck revitalization with platelet-rich plasma, 466
fillers for facial shaping, s129 (August)
yuraluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
minimally invasive techniques for periorbital rejuvenation, s118 (August)
MyoScience Tissue Remodeling Device for (CTR), 577
SkinMedical launches new Rejuvenize Peel™ (PP), 418
Fameclodix, safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
Familial pityriasis rubra pilaris (CR), 844
Fat
autologous, for facial shaping, s129 (August)
dual-wavelength laser lipolysis treatment of lipomas (CR), 387
fat necrosis/panniculitis and polyarthritis associated with pancreatic acinar cell carcinoma (CR), 1145
fat transplantation in treatment of morphea, 1213
FDA issues warning letters about claims regarding lipodissolve (PP), 874
laser lipolysis with 980 nm diode laser, s58 (May)
monophasic, cohesively-polydensified-matrix crosslinking-technology-based HA filler for facial lipoatrophy in HIV-infected patients (CR), 690
PureGraft™ System receives marketing clearance (PP), 723
SmartLipo Triplex™ for liposuction (PP), 80
Zeltiq receives FDA clearance (PP), 1552
Fellowships, identifying the right dermatologic surgery fellowship for you (RR), 421
Fexofenadine, for chronic idiopathic urticaria, 503
Field cancerization, for actinic keratoses, s45 (May)
Fluconazole cutaneous fixed drug eruption to (CR), 1025
Stevens-Johnson syndrome associated with (CR), 727
Fluocinolone acetonide, therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
5-Fluorouracil
medical and surgical management of keloids, 1249
topical successful treatment of cutaneous T-cell lymphoma with topical (CR), 1017
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 577
Fractional eyelift, prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser, 16
Fractionated laser therapy
appearance of burn scar after CO2 fractional laser treatment (CTR), 727
comparsion of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractional laser system (CTR), 84, 187, 425, 1035, 1155, 1289
effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155
first fractional laser FDA cleared for stretch marks (PP), 418
fractional photothermolysis for depressedalar scar following Mohs micrographic surgery (CR), 66
Groove Optic™ for Lux2940™ for fractional skin resurfacing (PP), 183
of mature thermal burn scars (CR), 389
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1429
ultrapulsed fractional CO2 laser for post-traumatic and pathological scars, 1328
Fungal infection
antifungal activity and nail permeation of innova- tion in distal subungual onychomycosis (CTR), 577, 1155
safety and efficacy of new topical keratolytic treatment (CTR), 1155
for targeting symptoms of inflammatory scalp disorders, 41
pharmacokinetics and safety of luliconazole solution tion in distal subungal onychomycosis (CTR), 577, 1155
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538
study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
TDF 067 onychomycosis study (CTR), 1538
treating onychomycosis (CTR), 187, 425
FV-100, vs. valacyclovir for herpes zoster (CTR), 1035
G
Gabapentin, for erythromelalgia (CR), 565
Garlic, for alopecia, 537
GDC-0049, efficacy and safety in patients with advanced BCC (CTR), 82, 285
Gefitinib cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
drug-associated acne and acneiform eruptions, 627
for recurrent or metastatic SCC of skin (CTR), 883
Gencitabine, and docetaxel with or without bevacizu- mab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
Genetics
celecoxib inhibition of genetic BCC (PP), 418
pathogenesis, genetics and medical treatment of patterned hair loss, 1412
steroid sulfate gene deletion in Egyptian males with X-linked ichthyosis, 1192
voriconazole-induced photosensitivity/photodagi- ning in X-linked chronic granulomatous disease (CR), 562
Genital warts, FDA approves new indications for HPV vaccine (PP), 80
Glaucam drugs, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
Glucose-6-phosphate dehydrogenase deficiency, safety of dapsone in, 532
Glutamate, to suppress recurrent herpes labialis (CTR), 285
Glycolic acid, tolerability and efficacy of novel formulation in treatment of melasma, 215
Gold, drug-associated acne and acneiform eruptions, 627
Golimumub, for psoriasis and psoriatic arthritis, 947
Graft-versus-host disease (GVHD), Soligenix study of ortecel for prevention of (PP), 1033
Granulocyte colony-stimulating factor, drug-associated acne and acneiform eruptions, 627
Green tea for cancer-related alopecia, 537
cosmeceuticals in clinical practice, s62 (May)
GSK2132231A antigen-specific immunothera- peutic, in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
Hair
modified scalpel in hair restoration (BC), 1266
topic cidofovir for prevention of hair growth (CTR), 82
Hair loss
bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
botanical approaches to alopecia, 537
Heliocare®

efficacy and safety

Hedgehog pathway inhibitor, benzyl alcohol lotion 5% for (PP), 572

Head lice,

Hand sanitizers,

unilateral lichen planus pigmentosus mimicking

efficacy and safety of new topical keratolytic treat-

Halogens,

treatment of androgenetic alopecia in females, 12

for androgenetic alopecia in females (CTR), 1446

treatment of alopecia areata of scalp with intra-

spironolactone pills vs. minoxidil lotion in female

safety and pharmacokinetics of new formulation

pathogenesis, genetics and medical treatment of

new study implicates autoimmune mechanisms

Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
treatment of androgenetic alopecia in females, 12 beam (CTR), 1446

Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
treatment of androgenetic alopecia in females, 12 beam (CTR), 1446

Halobetasol propionate ointment, efficacy of

Ultravate ointment in combination with Lac-

Hydrin cream for psoriasis (CTR), 285, 577,

Halogen, drug-associated acne and acneiform eruptions, 627

Hand lesions
efficacy and safety of new topical keratolytic treat-
ment for palmoplantar keratoderma, 1512
increased mast cell density in capucitabine-
induced hand-foot syndrome (CR), 268
rapid improvement in digital ischemia and acral
contracture in colloidion baby treated with
topical tazarotene (CR), 713
unilateral lichen planus pigmentosus mimicking
capolentiginosus melanoma (CR), 841

Hand sanitizers, FDA warns consumers in Puerto Rico of harmful bacteria in (PP), 874

Head lice, benzyl alcohol lotion 5% for (PP), 572

Hedgehog pathway inhibitor, efficacy and safety of

GDC-0449 in patients with advanced RCC
(CTR), 82, 285

Helcocare® (PP), 187

Hemangiomas, infantile
corticosteroid treatment impairs immune function
(PP), 1033
current treatments for (NVR), 176
pulsed dual-wavelength 585 and 1064 nm in
management of, 310

Hemodialysis patients, safety and efficacy of oral

nafuafurine HCl (AC-820) for uremic pruritus in
(CTR), 82, 285

Hemostasis, comparative efficacy and safety of
topical hemostatic powder and sterile
compressed foam sponge in second intention
healing after Mohs micrographic surgery, 137

Heparin necrosis, drug therapy for, 341

Herbal remedies
for alopecia, 537
orogeno-based ointment with antimicrobial activ-
ity against MRSA, 377

Hereditary angioedema, FDA approval of ecal-
lanotide for (PP), 572

Hereditary hemochromatosis (NVR), 719

Herpes gestationis (NVR), 1297

Hepetic disease
EPB-348 for herpes zoster (CTR), 1035
FDA approves Qutenza for postherpetic neural-
gia (PP), 282
FV-100 vs. valacyclovir for herpes zoster (CTR), 1035
oral glutamine to suppress recurrent herpes
labialis (CTR), 285
safety and pharmacokinetics of famciclovir single
1,500 mg dose in adolescents with recurrent
herpes labialis (CTR), 285
Hexapeptide-7, efficacy on menopausal skin, 49

Histology
annular leukocytoclastic vasculitis associated with
sorafenib (CR), 897
cutaneous fixed drug eruption to fluconazole (CR), 1025
cutaneous lupus erythematosus and anti-TNF-α
therapy (CR), 1283
eruption secondary to Taxotere (CR), 1534
familial pityriasis rubra pilaris (CR), 844
histopathologic identification of dermal filler
agents, 1072
immunosustains used in Mohs surgery, 760
increased mast cell density in capucitabine-
induced hand-foot syndrome (CR), 268
intralesional interferon alpha-2b for BCC of nasal
pyramid, 381
isoeotinin-induced effects of mast cells on
wound healing, 1207
lichen planus pigmentosus (CR), 841
localization and histology of injected hyaluronic acid
in excised nasolabial fold tissue (CR), 399
loculated argrigia secondary to acupuncture (CR),
1019
macular hypomelanosis in pregnant African
American woman with toxic nodular goiter
(CR), 393
Mehs surgery for melanoma in situ, 786
nephrogenic systemic fibrosis, 829
non-Hodgkin’s B-cell lymphoma in a psoriatic
patient (CR), 1277
oral lichenoid drug reaction associated with anti-
hypertensive and hydropoglycim drugs (CR), 73
osteoinvasive subungual melanoma (CR), 159
parasthesia, panniculitis and polyarthritis syn-
drome (CR), 1145
porokeratosis in patient with hepatitis of unclear
etiology (CR), 258
postpubertal eruptive synringoma triggered with
antiepileptic drugs (CR), 707
primary cutaneous angioimmunoblastic T-cell
lymphoma (CR), 851
rapid improvement of pyoderma gangrenosum
after infliximab treatment (CR), 702
sorafenib-induced psoriasisfom eruption in
patient with metastatic thyroid carcinoma
(CR), 169
TH17 in regression of metastatic melanoma to
primary dhiphycrypone, 1368
urticarial hypersensitivity reaction caused by
temozolomide (CR), 1142
Wong type dermatomasisis, 1475
Histoplasmosis, atypical presentation in a patient
with psoriasis and psoriatic arthritis on inflix-
imab therapy (CR), 57
Hodgkin’s lymphoma, development under bex-
arenone treatment for Sézary syndrome (CR),
1014
Human immunodeficiency virus (HIV) disease,
monophasic, cohesive-polycondensed-matrix
linking-technology-based HA filler for
facial lipoatrophy in HIV-infected patients (CR),
690
Restylane and Perlane in correction of peri-oral
wrinkles (CTR), 187
tolerance and efficacy of novel formulation in
treatment of melasma, 215
treatment of facial atrophic scars with Esthélis,
1507
treatment of forehead/glabellar rhytide complex
with combination botulinum toxin A and
hyaluronic acid vs. botulinum toxin injection
alone (CTR), 1538
Hydantoin, drug-associated acne and acneiform
eruptions, 627
Hydrotalcisone hydrocortisone, silicone and vitamin E lotion for
keloids and hypertrophic scars, 514
pediatric indication for Locoid Lipocream® cream
(PP), 80
Hydophilic molecules, stratum corneum permeation and percutaneous drug delivery
enhanced by cropyneumatic and photopneu-
matic technologies, 1528
Hydroquinone
toleration vs. azelaic acid in melasma (CTR), 727
toleration and efficacy of novel formulation in
treatment of melasma, 215
treating photodamage of décolletage area with
novel copper zinc malonate complex plus
retinoin and, 220
Hydroxychloroquine
efficacy in chronic urticaria (CTR), 1155
successful treatment of perniosis with, 1242
Hydroxyidine, Mylan receives approval for hy-
droxidine hydrochloride tablets (PP), 1160
Hyperhidrosis, practical applications of a new
botulinum toxin, s31 (March)
Hyperkeratosis, efficacy and safety of new topical
keratolytic treatment for, 1512
Hypersensitivity reactions. See also Drug reac-
tions/toxicity
fatal toxic epidermal necrolysis due to cardiac
avioration dye (CR), 837
sublingual immunotherapy against latex sensitiv-
ity (PP), 183
urticarial hypersensitivity reaction caused by
temozolomide (CR), 1142
Hypoglycemic drugs, oral lichenoid drug reaction
associated with antihypertensive drugs and
(CR), 73
Hypothalamic-pituitary-adrenal (HPA) axis, safety
and HPA axis effects of two-compound oint-
ment containing calcipotriene/betamethasone
dipropionate for psoriasis, 969

Ichtiones, syndromic, novel treatment for (CTR),
1155
Ichtiones, X-linked, steroid sulfatase gene dele-
tion in Egyptian males with, 1192
Idiopathic guttate hypomelanosos, pimecolimus for (BC), 238
IDP-107, safety and efficacy in patients with acne vulgaris (CTR), 1446
IDP-108, topical, safety and efficacy vs. vehicle in onychomycosis (CTR), 285, 577, 1538
ILV-095, evaluation of single dose in psoriasis subjects (CTR), 285, 577, 1035, 1446
Imatinib
drug-associated acne and acneiform eruptions, 627
in scleroderma (PP), 80
Imiquimod cream for actinic keratoses, s45 (May)
development of subacute cutaneous lupus erythematous associated with use of imiquimod to treat AK (CR), 1022
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101
FDA approves Zyclarla™ (PP), 723
generic approval of (PP), 572
for infantile hemangiomas (NVR), 176
medical and surgical management of keloids, 1249
Perrigo announces FDA approval for (PP), 1552
in treatment of morphea, 1213
Immune function
CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432
effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883
impaired by corticosteroids for infantile heman-giomas (PP), 1033
isotretinoin-induced effects of mast cells on wound healing, 1207
stains in skin, 921
ustekinumab effects on primate/human antigen-recall and humoral immune response functions, 677
Immunomodulators
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022
drug-associated acne and acneiform eruptions, 627
etanercept for chronic urticaria (CTR), 1155
etanercept for familial pityriasis rubra pilaris (CR), 285
etanercept for recalcitrant cicatricial pemphigoid (CR), 68
etanercept for recurrent cicatricial pemphigoid (CR), 68
etanercept for lichen planus (CTR), 187, 425, 577
generic approval of imiquimod cream 5% (PP), 572
how and when to use biologics in psoriasis, s106
Injectable biologist and U0279 combination therapy for psoriasis (CTR), 285
long-term safety and efficacy of etanercept in psoriasis, 928
progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005
prospective new biologic therapies for psoriasis and psoriatic arthritis, 947
rapid improvement of pyoderma gangrenosum after infliximab treatment (CR), 702
safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 883
safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538
safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
safety study of clinical and immune effects of phosphodiesterase-4 inhibitor in cutaneous lupus (CTR), 1538
thalidomide and analogues, 814
use in biologic therapies in pedestrian psoriasis, 975
ustekinumab vs. etanercept for psoriasis (PP), 572
Immunosuppression, multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet’s disease (CR), 152
Immunotherapy
dendritic cells and T cells in, 1383
dendritic cells in potential role for complement in immune evasion by Mycobacterium leprae, 1373
role of complement in dendritic cell control of T-cell subsets (editorial), 1364
TH17 in regression of metastatic melanoma to topical dipencyprone, 1368
GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
IV immunoglobulin therapy for scleromyxedema (CR), 285, 577
MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
sublingual, against latex sensitivity (PP), 183
Impetigo
impetigo herpetiformis in pregnancy (NVR), 1297
retapamulin vs. linezolid in treatment of SttL and impetigo due to MRSA (CTR), 82, 1538
Incibotulinumtoxin A. See also Botulinum toxin
FDA approves Merz Pharmaceuticals’ Xeomin® (PP), 1455
Incontinentia pigmenti, delayed onychodystrophy of, 350
Indoor tanning tax (PP), 282
Infantile hemangiomas
current treatments for (NVR), 176
pulsed dual-wavelength 595 and 1064 nm in management of, 310
Infection
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
dermatologic emergencies (NVR), 1249
PEG-interferon alfa-2b and UV light therapy in psoriasis and psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
potential role for complement in immune evasion using off-patent antibiotics for MRSA (CTR), 1538
TR-701 for bacterial skin infections (CTR), 1538
using off-patent antibiotics for MRSA (CTR), 1538
Inflammation
anti-inflammatory effects of topical dapsone for acne, 667
effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330
multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in treatment of inflammatory facial dermatoses (BC), 234
properties of benzoyl peroxide, 482
thalidomide and analogues for immunomodulation of inflammatory and neoplastic disorders, 814
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
Infliximab
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
drug-associated acne and acneiform eruptions, 627
how and when to use biologics in psoriasis, s106
(August)
rapid improvement of pyoderma gangrenosum after treatment with (CR), 702
use in pediatric psoriasis, 975
Ingenol mebutate gel, for actinic keratoses, s45 (May)
Insulin injections, cutaneous nontuberculous mycobacterial abscesses associated with (CR), 1439
Integra. See Collagen-glycosaminoglycan copolymer
Intense pulsed light, current guide to laser and light-based therapies for acne, 614
Interferon
Helix BioPharma and topical interferon alpha-2b for anogenital warts (PP), 723
interferon-alpha for infantile hemangiomas (NVR), 176
intralesional interferon alfa-2b for BCC of nasal pyramid, 381
medical and surgical management of keloids, 1249
PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883
pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
Interleukin-6, effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330
Interleukin-12/23 inhibitors
how and when to use biologics in psoriasis, s106
(August)
for psoriasis and psoriatic arthritis, 947
Internet
sales of isotretinoin (PP), 282
Sciton launches Japanese language website (PP), 1160
Intrahepatic cholestasis of pregnancy (NVR), 1297
Intrauterine devices, drug-associated acne and acneiform eruptions, 627
Intravenous immunoglobulin (IVIG) with or without cyclophosphamide in pemphigus (CTR), 1289
for scleromyxedema (CR), 263
Ipilimumab
for metastatic melanoma (PP), 1160
in young patients with advanced or refractory solid tumors (CTR), 883
Iraq - prevalence of skin disease in deployed dermatology clinic in, 210
Iressa®. See Gefitinib
Iron overload and cutaneous disease (NVR), 719
Isoniazid, drug-associated acne and acniform eruptions, 627
Isotretinoin (PP), FDA calls for FDA to address Internet sales of (PP), 282 effects of mast cells on wound healing induced by, 1207 inflammatory bowel disease and (NVR), 278 as monotherapy for sebaceous hyperplasia (CR), 699 trends in use for acne vulgaris, 519
Istodax X. See Romidepsin
Itraconazole comparison of SUBA™-itraconazole with SPO-RANOX™ for onychomycosis (CTR), 187, 285, 425 efficacy in BCC (CTR), 883, 1035

J

K
Kalbitor. See Ecaltantide
Keloids collagen-glycosaminoglycan copolymer for severe chest keloids, 542 evidence-based appraisal of lasers for scars, 1355 medical and surgical management of, 1249 tolerability and efficacy of two topical therapies for, 514 Keratinocytes efficacy of hexapeptide-7 on menopausal skin, 49 Keratinocytes medical and surgical management of, 1249 evidence-based appraisal of lasers for scars, 1355 fractional photothermolysis for depressedalar scar following Mohs micrographic surgery (CR), 66 Groove Optic™ for Lux2940™ for fractional skin resurfacing (PP), 183 Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446 laser lipoylalipoproteinlipolysis with 980 nm diode laser, s58 (May) laser treatment for fresh surgical scars and mature scars (CR), 727, 1156 medical and surgical management of keloids, 1249 multi-wavelength and coherence confocal reflec-tance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035 Nd:YAG laser for acne keloidalis nuchae (CR), 569 new SkinMedica ablative post-procedure kit (PP), 418 onychomycosis therapy, 1109 prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser — the fractional eyelift, 16 pulsed-dual-wavelength 595 and 1064 nm in management of hemangiomas, 310 pulsed dye laser for infantile hemangiomas (NVR), 176 Sloneton launches better safety and more efficacy at annual meeting (PP), 418 single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341 SmartLipo Triplex™ for liposuction (PP), 80 Solta Medical to buy Aesthera Corp. (PP), 418 “tattoo blow-out” pigment spread treated with NS-Nd:YAG laser (CR), 1429 tattoo treatment with alexandrite laser with Nd:YAG laser handpieces pumped by alexan-drite treatment beam, 1333 treating onychomycosis (CTR), 187, 425, 1538 treatment of androgenetic alopecia in females, 12 beam (CTR), 1446 treatment of burn scar with CO2 fractional laser (CR), 173 treatment of CO2 laser induced hypopigmentation with ablative fractional laser resurfacing (CR), 1420 treatment of melanoma with topical creams alone, CO2 fractional ablative resurfacing alone, or combination of the two, 315 treatment of surgical scars with pulsed dye laser (CTR), 727 ultrapulsed fractional CO2 laser for post-traumatic and pathological scars, 1328 Zerona now FDA-approved for body slimming (PP), 1456 Latanoprost, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 727

L
Lac-Hydrin® cream. See Ammonium lactate Lantoprost, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289

Levocetirizine for chronic idiopathic urticaria, 503 for pruritus in atopic dermatitis (CR), 82 Levodopa, phase 1 study of ND0611 dermal patch (PP), 1033

Leveronorgestrel implants, drug-associated acne and acniform eruptions, 627
Lice, benzyl alcohol lotion 5% for head lice (PP), 572 Lichen planus apremilast for (CTR), 577, 883 cutaneous and mucosal, efficacy of metronidazole for, 1186 etanercept in (CTR), 187, 425, 577 lichen planus pigmentosus mimicking acral len-tiginous melanoma (CR), 841 oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73 of oral mucosa or skin, safety and effectiveness of etanercept for (CTR), 577, 883

Lidocaine effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097
Emervel Classic Lidocaine vs. Juvéderm Ultra Plus for facial wrinkles and folds (CTR), 1538 Emervel Deep Lidocaine vs. Juvéderm Ultra Plus for facial wrinkles and folds (CTR), 1538 Juvéderm X XC with lidocaine (PP), 418 pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577 safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500 Light therapy, current guide to laser and light-based therapies for acne, 614 Linseed versus CEM-102 in bacterial skin infections (CTR), 1538 versus retapamulin in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538 Lip lip tenting technique for augmentation of, 559 PDT to treat actinic damage in patients with SCC of (CR), 82, 1289 Lipatropathy, monophasic, cohesives-polydensi-fied-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690 Lipid dissolve, FDA warning letters about claims regarding (PP), 874 Lipolysis with 980 nm diode laser, s58 (May) dual-wavelength laser lipolysis treatment of (CR), 387 Lipomas, dual-wavelength laser lipolysis treatment of (CR), 387 Liposuction, SmartLipo Triplex™ for (PP), 80 Lithium, drug-associated acne and acniform
nail fungus (CTR), 187, 425
tDTD 067 onychomycosis study (CTR), 1538
treating onychomycosis (CTR), 187, 425, 1538
Nelfinavir HCl (AC-820), safety and efficacy in subjects on haemodialysis with uraemic pruritus (CTR), 82

Nanotechnology
dermal effects of nanoparticles, 475
nanotechnology and the Nanodermatology Society (IC), 879
sunscreen update: controversies, what’s safe, what’s next (NVR), 1451
as topical therapeutic strategy for vascular dysfunction (RR), 574

Neck and face revitalization, with platelet-rich plasma, 466
Necrotizing xanthogranuloma, generalized, lenalidomide for (CR), 273
Necrotizing fasciitis, drug therapy for, 341
Necrotizing vasculitis, with platelet-rich plasma, 466

Neoplasia
ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
alemuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883, 1035
bevacizumab for angiosarcoma (CTR), 285
bimatoprost ophthalmic solution in promoting rapid wound re-epithelialization and BCC clearance (CTR), 883
ipilimumab for metastatic melanoma (PP), 1160
ipilimumab in young patients with advanced or refractory solid tumors (CTR), 883
lstodax for cutaneous T-cell lymphoma (PP), 183
keratoacanthomas, 117
lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 883
MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
management of Merkel cell carcinoma with emphasis on small primary tumors, 105
Merkel cell carcinoma, 779
Mhs surgery for melanoma in situ, 786
multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet’s disease (CR), 152
multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035
N-acetylcysteine to reduce melanoma risk (PP), 183
new melanoma staging system (NVR), 1029
nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sun-damaged melanoma (CTR), 883
non-Hodgkin’s B-cell lymphoma in a psoriatic patient (CR), 1277
osteonc invasive subungual melanoma (CR), 159
patient with nevoid BCC syndrome treated successfully with PDT (CR), 167
PDT to treat actinic damage in patients with SCC of lip (CR), 82, 1289
PTD using ALA in treating patients with skin cancer (CTR), 82
PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883
pegylated interferon for children with high-risk melanoma (CTR), 722, 1289
population education in preventing skin cancer: from childhood to adulthood, 112
in pregnancy (NVR), 1297
promising results of metastatic melanoma phase I trial of PLX4032 (PP), 1455
rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
role of phototherapy in cutaneous T-cell lymphoma, 764
maintenance phototherapy, 800
safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035
sorafenib-induced psoriasiform eruption in patient with metastatic thyroid carcinoma (CR), 169
successful treatment of cutaneous T-cell lymphoma with topical 5-fluorouracil (CR), 1017
systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
TH17 in regression of metastatic melanoma to topical diphencyprone, 1368
thalidomide and analogues for immunomodulation of inflammatory and neoplastic disorders, 814
trial of Dermacorder for detecting malignant skin lesions (CTR), 883
UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289
vaccine therapy in stage IV cutaneous melanoma (CTR), 1289
ZD1389 for recurrent or metastatic SCC of skin (CTR), 883

Nephrogenic systemic fibrosis, 929

News, Views, and Reviews (NVR), 76, 176, 278, 412, 569, 719, 871, 1029, 1289, 1451, 1545
Nicinamide, cosmeceutical in clinical practice, s62 (May)
Nigerian plants, for cancer-related alopecia, 537
Nilitinib, in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sun-damaged melanoma (CTR), 883
Nitric oxide, effect of thalidomide on production in RAW 264.7 cells, 330

Ocular cicatrical pemphigoid
etanercept for (CR), 68
rituximab in (CTR), 187, 425, 577, 1289
Omalizumab, efficacy and safety in bullous pemphigoid (CTR), 187, 425, 577, 1289
Onion extract gel, for keloids and hypertrophic scars, 514
Onion juice, for alopecia, 537
Onychodystrophy, delayed, of incontinentia pigmenti, 350
Onychomycosis
antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
comparison of SUBA™-itraconazole with SPO-RANOX® for (CTR), 185, 245, 425
efficacy and safety of iontophoretic application of terbinafine gel in (CTR), 577, 1155
light therapy for (CTR), 285, 577, 1155
pharmacokinetics and safety of ituliconazole solution in (CTR), 577, 1155
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
safety and efficacy of topical IDP-108 vs. vehicle in (CTR), 285, 577, 1538
study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
TDT 067 study (CTR), 1538
treatment for, 1109
treatment of (CTR), 187, 425, 1538
Oral contraceptives, trends in use for acne vulgaris, 519
Oral lesions
etanercept for recalcitrant cicatrical pemphigoid (CR), 68
oral glutamine to suppress recurrent herpes labialis (CTR), 285
oral lichenoid drug reaction associated with anti-HCV antibodies and pyogenic drug eruptions (CR), 73
retinoids for palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis (CR), 1151
safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577, 883 safety and pharmacokinetics of famicloivir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 286 Oregano-based ointment, with antimicrobial activity against MRSA, 377 Oseltamivir (NVR), 76 Osteoimvasive subungal melanoma (CR), 159 Oxandrolone, in treatment of decubitus ulcers (CR), 711 Oxidative stress dose-dependent antioxidant function of resveratrol, 1523 efficacy and tolerance of novel phenolic antioxidant skin care system, 1480 oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11 Oxybenzone, sunscreen update: controversies, what's safe, what's next (NVR), 1451

P

P-3051, antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525 Pain, with Radiesse® with lidocaine for nasolabial folds (CTR), 577 Palmarplantar keratoderma, efficacy and safety of new topical keratolytic treatment for, 1512 Palmitoylthetanolamide-containing cream, for atopic dermatitis, 334 Pancreatitis,panniculitis and polyarthritis syndrome (CR), 1145 Panniculitis,mycosis fungoides/Sézary syndrome (CR), 1145 Paralysis, histopathologic identification of dermal filler agents, 1072 Parastisosis, delusions of, 1072 Parkinson’s disease, phase 1 study of ND061 dermal patch (PP), 1033 Patient education, approaching psoriasis: patient-physician relationships, patient education and choosing the right topical vehicle, 908 Pediatric dermatology corticosteroids for infantile hemangiomas impair immune function (PP), 1033 current treatments for infantile hemangiomas (NVR), 176 dermatologic indicators of eating disorders (NVR), 412 Epiduo® pediatric acne study (CTR), 1155 novel treatment for syndromic ichthyoses (CTR), 1155 pediatric indication for Locoid Lipocream® cream (PP), 80 pediatric longitudinal evaluation of long-term safety of Protopic® for atopic dermatitis (CTR), 1146 pegylated interferon for children with high-risk melanoma (CTR), 727, 1289 population education in preventing skin cancer: from childhood to adulthood, 112 pulsed dye-wavelength 532 and 1064 nm in management of hemangiomas, 310 rapid improvement in digital ischemia and acral contracture in colloidon baby treated with topical tazarotene (CR), 713 safety and pharmacokinetics of famicloivir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285 topical tretinoin gel and acne in preadolescents (PP), 1033

topical vitamin B12 for childhood atopic dermatitis (CTR), 1155, 1446 use of biologic agents in pediatric psoriasis, 975 voriconazole-induced photosensitivity/photog- ing in X-linked chronic granulomatous disease (CR), 562 PEG-interferon alfa-2b, and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883 Pemphigus vulgaris IVIG with or without cyclophosphamide in (CTR), 1289 pemecrulimium cream for cutaneous lesions of, 684 Peri illy alcohol, topical, in treating patients with sun damaged skin and AK (CTR), 82 Perioral region, injection techniques for revolu- mization with hyaluronic acid, 367 Periorbital region controlled multi-center study evaluating the efficacy of Vivite Skin Care for photogaging of face, eye and mouth, 22 effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289 minimally invasive techniques for periorbital rejuvenation, s118 (August) novel sonic infusion system for periorbital rhy- tides, 1121 prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16 Peripheral artery disease combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289 safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289 Pemiosis, successful treatment with hydroxyclo- roquine, 1242 Pharmacokinetics safety and pharmacokinetics of famicloivir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285 safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446 safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035 and safety of fulclozolone solution in distal subun- gual onychomycosis (CTR), 577, 1195 Phosphodiesterase-4 inhibitor, efficacy after Mohs micrographic surgery with postoperative PDT (CR), 143 rapid wound re-epithelialization and BCC clearance after Mors micrographic surgery with postoperative PDT (RR), 878 to treat actinic damage in patients with SCC of lip (CTR), 82, 1289 in treatment of morphea, 1213 using ALA in treating patients with skin cancer (CTR), 82 utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treat- ments (CR), 864 Photoneumatic technology, stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by, 1528 Photosensitivity, voriconazole-induced photosen- sitivity/photogaging in X-linked chronic granulomatous disease (CR), 562 Phototherapy... current guide to laser and light-based therapies for acne, 614 light therapy to treat toe nail fungus (CTR), 285, 577, 1165 PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883 role in cutaneous T-cell lymphoma, 764 for toenail fungus (CTR), 285, 577 in treatment of morphea, 1213 usefulness of narrowband UBV as monotherapy for chronic plaque psoriasis, 989 Pigmentation azelaic acid vs. hydroquinone in melasma (CTR), 727 effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289 failure of botulinum toxin treatment for localized vitiligo, 1092 localized argyria secondary to acupuncture (CR), 1019 macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393
INDEX OF ARTICLES

Polidocanol
approval for sclerotherapy (NVR), 871
FDA approval for small varicose veins (PP), 723
Poly-Lactic acid (PLLA)
fillers for facial shaping, s129 (August)
histopathologic identification of dermal filler agents, 1072
use in people of color, 451
Polyethyleneimine/bovine collagen,
histopathologic identification of dermal filler agents, 1072
Polyethyleneimine/carboxylgluconate,
histopathologic identification of dermal filler agents, 1072
Population education, in preventing skin cancer:
from childhood to adulthood, 112
Prorokariosis, in patient with hepatitis of unclear etiology (CR), 258
Porphyria cutanea tarda (NVR), 719
Postherpetic neuralgia, FDA approves Qutenza® for (PP), 282
Potassium tinityl phosphate laser, current guide to laser and light-based therapies for acne, 614
Pregnancy
dermatology in (NVR), 1297
macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393
Pressure ulcers, oxandrolone treatment of (CR), 711
Prevention
ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
population education in preventing skin cancer: from childhood to adulthood, 112
Soligenix study of orBec® for prevention of GVHD (PP), 1033
systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
topical cidofovir for prevention of hair growth (CTR), 82
Primula, for alopecia, 537
PRK 124 lotion, long-term efficacy and safety in rosacea, 647
Procyadinids, for alopecia, 537
Progressive multifocal leukoencephalopathy, in two psoriasis patients treated with efalizumab (CR), 1005
Propanolol, for infantile hemangiomas (NVR), 176
Prostaglandin eye drops, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
Protopic®, pediatric longitudinal evaluation of long-term safety for atopic dermatitis (CTR), 1466
Provenge (Sipuleucel-T), role of complement in dendritic cell control of T-cell subsets (editorial), 1163
Prurigo of pregnancy (NVR), 1297
Pruritic folliculitis of pregnancy (NVR), 1297
Pruritus
in atopic dermatitis, 488
butilinum toxin type A reduces itch (PP), 282
efficacy of topical antihistamines for, 992
Ertaczo® for (PP), 80
management with Zyzal in atopic dermatitis (CTR), 82
in pregnancy (NVR), 1297
safety and efficacy of oral nalufsufide HCl (AC-820) in subjects on hemodialysis with uremic pruritus, 82
Psoralen-UVa, drug-associated acne and acneiform eruptions, 627
Psoriasis
Ain457 regimen finding study in (CTR), 285
alfacalcidol treatment for up to one year, 1491
aytypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
bicillin LA versus placebo for psoriasis unresponsive to topical medications (CTR), 425
butulimum toxin for (CTR), 82, 1033
bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation (CR), 1010
clinical activity, safety, and tolerability of SRT2104 in subjects with (CTR), 1446
dose finding study of ABB0171 assessing psoriasis area and severity index in patients with (CTR), 285
efalizumab for resistant plaque (PP), 183
efficacy and safety of adding methotrexate to alefacept treatment for up to one year, 1491
fferent patterns and perceptions of treatment in alcoholics (CR), 405
therapeutic shampoos for targeting symptoms of scalp, 912, 1033 (August)
treatment in patients who have prior exposure to anti-TNF agents (CTR), 1155
Safety and efficacy of ustekinumab in patients with progressive multifocal leukoencephalopathy in a positive phase 2b clinical trial of apremilast for patient-physician relationships, patient education and choosing the right topical vehicle, 908
evidence-based review of coal tar preparations for infantile hemangiomas (NVR), 176
evaluation of single dose of IVL-095 in subjects with (CTR), 285, 577, 1033, 1446
evidence-based review of coal tar preparations for, 1258
FDA approves Glenmark’s calcipotriene ointment for (PP), 723
fluphenazine hydrochloride for (CTR), 187, 425, 1446
gent and when to use biologics in, s106 (August)
isable biologic and U0279 combination therapy for (CTR), 285
long-term safety and efficacy of etanercept in, 928
management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241
non-Hodgkin’s B-cell lymphoma in a psoriatic patient (CR), 1277
patient-physician relationships, patient education and choosing the right topical vehicle, 908
positive phase 2b clinical trial of apremilast for (PP), 282
pregnancy (NVR), 1297
progressive multifocal leuкоencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005
prospective new biologic therapies for psoriatic arthritis and, 947
safety and efficacy of BFH772 in patients with (CTR), 187, 425
safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for, 969
safety of teplizumab (MGA0031) in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577
scalp, 912, s101 (August)
thalidomide and analogues for, 814
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
treatment in alcoholics (CR), 405
treatment patterns and perceptions of treatment attributes, satisfaction and effectiveness among patients with, 938
use of biologic agents in pediatric patients with, 975
usefulness of narrowband UVB as monotherapy for chronic plaque psoriasis, 989
ustekinumab versus etanercept for (PP), 572
V8-201 for (CTR), 1033, 1446
Psoriatic arthritis
adult onset, certolizumab pegol for (CTR), 1446
aytypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
prospective new biologic therapies for psoriasis and, 947
safety and efficacy of ustekinumab in patients with (CTR), 1155
Psychosocial sequelae of acne, dermatologic indicators of purging behavior, 29
Psoriasis vulgaris, drug therapy for, 341
Psoralen-UVA
among patients with, 938
in inflammatory scalp disorders, 41
Psoralen-UVA, drug therapy for calciphylaxis, 341
treatment of atopic dermatitis with concurrent Atnabax and topical low-potency corticosteroids versus low-potency corticosteroid monotherapy (CTR), 883, 1033
Retinoids
AADAs calls for FDA to address Internet sales of isotretinoin (PP), 282
acne relapse rate of oral minocycline versus oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727
antimicrobial efficacy of benzoyl peroxide/ clindamycin phosphate gel versus clindamycin phosphate/tretinoin gel for acne vulgaris, 131
Atralin gel for rosacea (CTR), 1033, 1538
irradiation potential of tretinoin gel microsphere pump versus adapalene plus benzoyl peroxide gel, 988
isotretinoin and inflammatory bowel disease and (NVR), 278
isotretinoin as monotherapy for sebaceous hyperplasia (CR), 699
isotretinoin-induced effects of mast cells on wound healing, 1207
morning/morning regimen of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805
optimizing acne therapy with unique vehicles, s53 (May)
oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
Pyoderma gangrenosum, drug therapy for, 341
Pyoderma gangrenosum, rapid improvement after infliximab treatment (CR), 702
Pyratine-XR. See PRK 124 lotion
Q
Qutenza®. See Capsaicin
Race/ethnicity
optimizing acne therapy with unique vehicles, s53 (May)
oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
for palliative treatment of paraneoplastic acanthosis nigrans and oral florid papillomatosis (CR), 1151
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1033
sunscreen update: controversies, what’s safe, what’s next (NVR), 1446
systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
topical tretinoin gel and acne in preadolescents (PP), 1033
treating photodamage of decolletage area with novel copper zinc mellite complex plus hydroquinone and tretinoin, 220
trends in use for acne vulgaris, 519
Rifampicin, drug-associated acne and acneiform eruptions, 627
Ritusuximab, in ocular cicatricial pemphigoid (CTR), 187, 425, 577, 1289
Rocky Mountain spotted fever (NVR), 1545
Romidepsin, for cutaneous T-cell lymphoma (PP), 183
Rosacea
apremilast for (CTR), 727, 1033, 1538
Atralin gel for (CTR), 1033, 1538
changes in comedobidity and treatment utilization over time, 1402
combination therapy for (CTR), 187, 285, 425, 1538
efficacy and safety of CD07805/47 gel in subjects with facial erythema associated with (CTR), 1538
efficacy of topical azelaic acid gel plus oral doxycycline versus metronidazole gel plus oral doxycycline in, 607
long-term efficacy and safety of topical PRK 124 lotion for, 647
safety and efficacy of clindamycin and tretinoin gel for (CTR), 187, 285, 425, 1033, 1538
Retapamulin
in age of S. aureus antimicrobial resistance, 1198
versus linezolid in treatment of STIL and impetigo due to MRSA (CTR), 82, 1538
therapy of atopic dermatitis with concurrent Atnabax and topical low-potency corticosteroids versus low-potency corticosteroid monotherapy (CTR), 883, 1033
safety and efficacy of oral nalfurafine HCl (AC), 820) in subjects on hemodialysis with uremic osteodystrophy (CR), 859
safety and efficacy of oral nalfurafine HCl (AC), 820) in subjects on hemodialysis with uremic osteodystrophy (CR), 859
safety and efficacy of oral nalfurafine HCl (AC), 820) in subjects on hemodialysis with uremic osteodystrophy (CR), 859
Sildenafil, drug therapy for cutaneous T-cell lymphoma (PP), 183
Safety issues
clinical safety, and tolerability of SRT2104 in subjects with psoriasis (CTR), 1446
comparative efficacy and safety of topical humic acid powder and sterile compressed foam sponge in second intention healing after Mohs micrographic surgery, 137
comparison of safety and efficacy of ALA plus a 532 nm KTP laser versus 532 nm KTP laser alone for facial acne, 229
dapson gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
dose finding and safety study of oral LEQ506 in patients with advanced solid tumors (CTR), 883
efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82
efficacy and safety of AS015K in psoriasis (CTR), 1033, 1446
efficacy and safety of CD07223 gel in subjects with acne (CTR), 1446
efficacy and safety of CD07805/47 gel in subjects with facial erythema associated with rosacea (CTR), 1538
efficacy and safety of doxycycline and minocycline (CTR), 1033, 1446
efficacy and safety of ASP015K in psoriasis (CTR), 187, 425, 1446
efficacy and safety of topical 0.1% diclofenac gel in unique drug delivery system, 1500
etanercept for discoid lupus erythematosus (CTR), 1538
etanercept for discoat lupus erythematosus (CTR), 1538
efficacy and safety of dapsone in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients, 532
etanercept for facial acne vulgaris, 549
etanercept for facial acne vulgaris, 549
etanercept for keloids and hypertrophic scars, 514
etanercept for keloids and hypertrophic scars, 514
evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856
evidence-based appraisal of lasers for scars, 1355
fractional photothermolysis for depressed alar rim prior to wound closure (CTR), 1155
efficacy of spray silicone in alteration of burn scar (CTR), 727
evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856
evidence-based appraisal of lasers for scars, 1355
fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 727
efficacy of spray silicone in alteration of burn scar (CTR), 727
evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856
evidence-based appraisal of lasers for scars, 1355
fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 727
efficacy of spray silicone in alteration of burn scar (CTR), 727
evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856
evidence-based appraisal of lasers for scars, 1355
fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 727
efficacy of spray silicone in alteration of burn scar (CTR), 727
organ transplant recipients (CTR), 82
almetuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 888
bevacizumab for angiosarcoma (CTR), 285
BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1033
celiecoxib inhibition of genetic BCC (PP), 418
Charcot-Marie-Tooth disease and multiple malignant melanomas (CR), 164
complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727
correlation between skin carotenoid levels and previous history of (CTR), 1289
CTLA4-induced immune reactivation in CD28-deficient patients (CTR), 888
pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
population education in prevention: from childhood to adulthood, 112
in pregnancy (NVR), 1297
promising results of metastatic melanoma phase 1 trial of PLX4032 (PP), 1455
rapid wound re-epithelialization and BCC clearance after Mohs microscopic surgery with postoperative PDT (CR), 143
rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
role of phototherapy in cutaneous T-cell lymphoma, 764
maintenance phototherapy, 800
safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1033
successful treatment of cutaneous T-cell lymphoma, 764
systemic retinoids for chemoprevention of nonmelanoma skin cancer in high-risk patients, 753
TH17 in regression of metastatic melanoma to topical diphencyprone, 1368
thalidomide and analogues for, 814
treatment of Dermacorder for detecting malignant skin lesions (CTR), 883
UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289
vaccine therapy in stage IV cutaneous melanoma (CTR), 1289
ZD1839 for recurrent or metastatic SCC of skin (CTR), 883
Skin Cancer Foundation, Iredale Mineral Cosmetics receives Seal of Recommendation from, 572
Skin resurfacing
Groove Optic™ for Lux2940™ for (PP), 183
treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420
Sodium sulfacetamide 10%, sulfur emollient 5% foam, in treatment of inflammatory facial dermatoses (BC), 234
Soft tissue augmentation
attaining predictable aesthetic results with dermal fillers, 458
Belotero dermal filler close to FDA approval (PP), 1455
calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446
Emervel multiple lipidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
Emervel Deep Lipocaine versus Juvederm Ultra
Plus for facial wrinkles and folds (CTR), 1538
fillers for facial shaping, s129 (August)
hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
injection techniques for revolutionization of perioral region with hyaluronic acid, 367
monophasic, cohesives-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690
pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
treatment of facial atrophic scars with Esthélis, 1507
treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid versus botulinum toxin injection alone (CTR), 1538
use of injectable poly-L-lactic acid in people of color, 451
Sorafenib
annular leukocytoclastic vasculitis associated with (CR), 897
psoriasisiform eruption induced by, in patient with metastatic thyroid carcinoma (CR), 169
Soy, cosmeceuticals in clinical practice, s62 (May)
Spironolactone
spironolactone pills versus minoxidil lotion in female pattern hair loss (CTR), 577
in treatment of acne (NVR), 546
Squamous cell carcinoma (SCC)
dasatinib for unresectable or metastatic SCC (CTR), 285
dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
efficacy of PDT for recurrent SCC and BCC, 122
electrodessication and curettage versus excision for SCC, 773
electroninc brachytherapy for non-melanoma skin cancer (CTR), 1033
erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285
erlotinib in women with SCC of vulva (CTR), 1289
erlotinib prior to surgery or radiation in patients with SCC (CTR), 883, 1289
flexible scalp for minimally invasive and minimally scarving surgery for large scalp tumors, 1268
gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
human monoclonal antibody zanolimumab to Merkel cell carcinoma, 779
immunostains used in Mohs surgery, 760
intraleisional interferon alfa-2b for BCC of nasal pyramid, 381
ipilimumab for metastatic melanoma (PP), 1160
iron overload and (NVR), 719
Isotodax for cutaneous T-cell lymphoma (PP), 183
keratoacanthomas, 117
lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 888
MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
management of Merkel cell carcinoma with emphasis on small primary tumors, 105
Merkel cell carcinoma, 779
Mhs surgery for melanoma in situ, 786
multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet’s disease (CR), 152
multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1033
N-acetylcysteine to reduce melanoma risk (PP), 183
new melanoma staging system (NVR), 1029
nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883
osteoinvasive subungual melanoma (CR), 159
patient with nevoid BCC syndrome treated successfully with PDT (CR), 167
PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
PDT using ALA in treating patients with (CTR), 85
PEG-phoma with topical 5-fluorouracil (CR), 1017
Sodium sulfacetamide 10%, sulfur emollient 5% foam, in treatment of inflammatory facial dermatoses (BC), 234
Soft tissue augmentation
attaining predictable aesthetic results with dermal fillers, 458
Belotero dermal filler close to FDA approval (PP), 1455
calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446
Emervel multiple lipidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
Emervel Deep Lipocaine versus Juvederm Ultra
Plus for facial wrinkles and folds (CTR), 1538
fillers for facial shaping, s129 (August)
hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
injection techniques for revolutionization of perioral region with hyaluronic acid, 367
monophasic, cohesives-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690
pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
treatment of facial atrophic scars with Esthélis, 1507
treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid versus botulinum toxin injection alone (CTR), 1538
use of injectable poly-L-lactic acid in people of color, 451
Sorafenib
annular leukocytoclastic vasculitis associated with (CR), 897
psoriasisiform eruption induced by, in patient with metastatic thyroid carcinoma (CR), 169
Soy, cosmeceuticals in clinical practice, s62 (May)
Spironolactone
spironolactone pills versus minoxidil lotion in female pattern hair loss (CTR), 577
in treatment of acne (NVR), 546
Squamous cell carcinoma (SCC)
dasatinib for unresectable or metastatic SCC (CTR), 285
dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
efficacy of PDT for recurrent SCC and BCC, 122
electrodessication and curettage versus excision for, 773
electronic brachytherapy for non-melanoma skin cancer (CTR), 1033
erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285
erlotinib in women with SCC of vulva (CTR), 1289
erlotinib prior to surgery or radiation in patients with SCC (CTR), 883, 1289
flexible scalp for minimally invasive and minimally scarving surgery for large scalp tumors, 1268
multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1033
Statins in skin,
Stem cell transplantation
almetuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 898
combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289
hematopoietic stem cell support in patients with autoimmune bullous skin disorders (CTR), 1289
safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1298
Soligenix study of orbecc® for prevention of GVHD after (PP), 1033
Steroid sulfatase gene deletion, in Egyptian males with X-linked ichthyosis, 1192
Stevens-Johnson syndrome (NVR), 1545
bupropion-induced, with acute psoriatic exacerbation (CR), 1010
fluconazole-associated, 1272
Stress, relaxation strategies for patients during dermatologic surgery, 795
Stretch marks
first fractional laser FDA cleared for (PP), 418
Mederma® for (PP), 418
Sulfonamides, safety of dapsonre in patients with allergies to, 532
Sulfur, multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in treatment of inflammatory facial dermatoses (BC), 234
Sunburn, iron overload and (NVR), 719
Sunscreens
dermal effects of nanoparticles, 475
Iredale Mineral Cosmetics receives Seal of Recommendation from Skin Cancer Foundation, 572
oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
update: controversies, what’s safe, what’s next (NVR), 1446

T
t cells
CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432
and dendritic cells in immunotherapy, 1383
role of complement in dendritic cell control of subsets of (editorial), 1364
TH17 in regression of metastatic melanoma to topical diphenycpronine, 1368
T4NS liposome lotion, reduced number of AK with, 1519
Tacrolixumab
cost-effectiveness versus pimecrolimus cream for acne and acneiform eruptions, 627
for pruritus in atopic dermatitis, 488
drug-associated acne and acneiform eruptions, 1289
safety and efficacy of tazarotene foam in subjects with facial acne (CTR), 187, 425, 1446
topical, rapid improvement in digital ischemia and acral contracture in collodion baby treated with (CR), 713
TDD 0.05, in onychomycosis (CTR), 1538
Tea polyphenols, oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
treatment of forehead/glabellar rhytide complex with combination butotinin and hyaluronic acid versus butotinin alone (CTR), 1538
use of injectable poly-L-lactic acid in people of color, 451
Titanium dioxide, sunscreen update: controversies, what’s safe, what’s next (NVR), 1446
Topically dissolved oxygen (TDO), to amilorigate signs of photodamage (CTR), 187, 425
Torezolid phosphate, phase 3 study of (PP), 1160
Tocixoidal necrosis (NVR), 1545
due to cardiac catheterization dye (CR), 837
TR-701, for bacterial skin infections (CTR), 1538
Training, identifying the right dermatologic surgery fellowship for you (RR), 421
Transplant recipients, ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
Travatan. See Travoprost
Travoprost, effects of Xalatan, Travatan and Luminigan of skin pigmentation near eye (CTR), 1289
Tretinoin
acne relapse rate of oral minocycline versus oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 572, 727
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel versus clindamycin phosphate/tretinoin gel for acne vulgaris, 131
Atralin gel for rosacea (CTR), 1033, 1538
irritation potential of tretinoin gel microsphere pump versus adapalene plus benzoyl peroxide gel, 998
morning/morning regimen of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805
optimizing acne therapy with unique vehicles, s53 (May)
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1033, 1538
topical tretinoin gel and acne in preadolescents (PP), 1033
Tromethamine, effect of triamcinolone 0.1% cream occluded with hydrogel patch versus triamcinolone 0.1% cream without occlusion for eczema (CTR), 883
T-20
Trichloroacetic acid, utilizing combination or sequential treatment with 5-fluourouracil cream and destructive treatments (CR), 964
Triclosan, FDA reviewing safety of antibacterial soap ingredient (PP), 874
Trimethoprim-sulfamethoxazole, using off-patent antibiotics for MRSA (CTR), 1538
Tumor necrosis factor-α, effect of thalidomide on inflammatory and neoplastic disorders, 814
treatment of forehead/glabellar rhytide complex with combination butotinin and hyaluronic acid versus butotinin alone (CTR), 1538

U
U0279, and injectable biologic combination therapy for psoriasis (CTR), 285
U28
combination cell therapy for treatment of severe leg ischemia (CTR), 1289
drug therapy for Buruli ulcer, 341
FDA clearance of V.A.C. therapy for venous insufficiency ulcers (PP), 1160
oxandrolone in treatment of decubitus ulcers